Submission Details

Molecule(s):
C=CC(=O)Nc1cccc(C(=O)N2CCSCC2)c1

JOO-IND-6372a4f3-1

C=CC(=O)Nc1cccc(C(=O)N2CCSCC2)c1

O=C(Nc1cccc(C(=O)N2CCSCC2)c1)C(F)Cl

JOO-IND-6372a4f3-2

O=C(Nc1cccc(C(=O)N2CCSCC2)c1)C(F)Cl

CC#CC(=O)Nc1cccc(C(=O)N2CCSCC2)c1

JOO-IND-6372a4f3-3

CC#CC(=O)Nc1cccc(C(=O)N2CCSCC2)c1

C=CC(=O)N1CCN(Cc2cccc3ccccc23)CC1

JOO-IND-6372a4f3-4

C=CC(=O)N1CCN(Cc2cccc3ccccc23)CC1

CC#CC(=O)N1CCN(Cc2cccc3ccccc23)CC1

JOO-IND-6372a4f3-5

CC#CC(=O)N1CCN(Cc2cccc3ccccc23)CC1

O=C(C(F)Cl)N1CCN(Cc2cccc3ccccc23)CC1

JOO-IND-6372a4f3-6

O=C(C(F)Cl)N1CCN(Cc2cccc3ccccc23)CC1

piperazine-chloroacetamide Made Check Availability on Manifold View

Design Rationale:

Covalent fragments with more drug-like warheads as discussed on the forum. Fragments 786 and 0830 (together with 749 in an earlier proposal) have a different way of approaching the catalytic Cys 145. Testing these designs will show which approach is most suitable for which warhead.

Inspired By:
Discussion: